ES2147309T3 - Composiciones de ondansetron liofilizadas. - Google Patents

Composiciones de ondansetron liofilizadas.

Info

Publication number
ES2147309T3
ES2147309T3 ES95940208T ES95940208T ES2147309T3 ES 2147309 T3 ES2147309 T3 ES 2147309T3 ES 95940208 T ES95940208 T ES 95940208T ES 95940208 T ES95940208 T ES 95940208T ES 2147309 T3 ES2147309 T3 ES 2147309T3
Authority
ES
Spain
Prior art keywords
compositions
ondansetron
lyophilized
hydroxitriptamine
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95940208T
Other languages
English (en)
Spanish (es)
Inventor
Ian Keith Winterborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2147309(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Application granted granted Critical
Publication of ES2147309T3 publication Critical patent/ES2147309T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Fertilizers (AREA)
ES95940208T 1994-11-22 1995-11-20 Composiciones de ondansetron liofilizadas. Expired - Lifetime ES2147309T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (1)

Publication Number Publication Date
ES2147309T3 true ES2147309T3 (es) 2000-09-01

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95940208T Expired - Lifetime ES2147309T3 (es) 1994-11-22 1995-11-20 Composiciones de ondansetron liofilizadas.

Country Status (30)

Country Link
US (2) US5955488A (OSRAM)
EP (1) EP0793495B1 (OSRAM)
JP (1) JP3001264B2 (OSRAM)
KR (1) KR970706814A (OSRAM)
CN (1) CN1080118C (OSRAM)
AT (1) ATE193444T1 (OSRAM)
AU (1) AU704160B2 (OSRAM)
BE (1) BE1010250A3 (OSRAM)
BR (1) BR9509808A (OSRAM)
CY (1) CY2166B1 (OSRAM)
CZ (1) CZ285250B6 (OSRAM)
DE (1) DE69517332T2 (OSRAM)
DK (1) DK0793495T3 (OSRAM)
ES (1) ES2147309T3 (OSRAM)
FI (1) FI119355B (OSRAM)
FR (1) FR2727016B1 (OSRAM)
GB (2) GB9423511D0 (OSRAM)
GR (1) GR3033937T3 (OSRAM)
HU (1) HU226891B1 (OSRAM)
IL (1) IL116084A (OSRAM)
IT (1) IT1282352B1 (OSRAM)
MX (1) MX9703735A (OSRAM)
NO (1) NO306893B1 (OSRAM)
NZ (1) NZ296982A (OSRAM)
PL (1) PL181179B1 (OSRAM)
PT (1) PT793495E (OSRAM)
RU (1) RU2159614C2 (OSRAM)
TW (1) TW398976B (OSRAM)
WO (1) WO1996015785A1 (OSRAM)
ZA (1) ZA959821B (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
EP2042161A1 (en) * 1997-10-01 2009-04-01 Novadel Pharma Inc. Propellant-free spray composition comprising anti-emetic agent
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
ATE311227T1 (de) * 1999-12-01 2005-12-15 Natco Pharma Ltd Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
RU2162847C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона и его фармацевтически приемлемых солей
JP2004525083A (ja) * 2000-10-30 2004-08-19 テバ ファーマシューティカル インダストリーズ リミティド 塩酸オンダンセトロンの新規結晶及び溶媒和物形態並びにその製法
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
MXPA04010846A (es) * 2002-04-29 2005-01-25 Biogal Gyogyszergyar Proceso para preparar 1, 2, 3, 9-tetrahidro -9- metil-3 -[(2-metil -1h-imidazol -1-il) metil]- 4h- carbazol -4- ona.
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
CA2483532A1 (en) * 2002-04-30 2003-11-13 Biogal Gyogyszergyar Rt. Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005040123A1 (en) 2003-10-10 2005-05-06 Synhton B. V. Solid-state montelukast
DE602005027308D1 (de) * 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
DE602005016402D1 (de) * 2004-05-24 2009-10-15 Genvault Corp Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101432267A (zh) * 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
HRP20090341T1 (hr) * 2006-10-24 2009-07-31 Helsinn Healthcare S.A. Mekane kapsule koje sadrže palonosetron hidroksiklorid s poboljšanom stabilnosti i bioraspoloživosti
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
RU2363463C1 (ru) * 2007-11-14 2009-08-10 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства Лекарственное средство
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
EP2276739A1 (en) * 2008-04-25 2011-01-26 Synthon B.V. Process for making montelukast intermediates
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
KR101779991B1 (ko) * 2009-05-20 2017-09-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 병소성 전정 질환을 치료하기 위한 세로토닌 5-ｈｔ3 수용체 길항제의 용도
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
ES2975016T3 (es) 2016-04-14 2024-07-02 Sensorion (+)-Azasetrón para uso en el tratamiento de trastornos del oído

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084705B1 (en) * 1981-12-11 1987-01-14 JOHN WYETH & BROTHER LIMITED Process for preparing solid shaped articles
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
DK0793495T3 (da) 2000-10-09
GB2295318A (en) 1996-05-29
CZ285250B6 (cs) 1999-06-16
AU4173996A (en) 1996-06-17
IL116084A (en) 2000-01-31
MX9703735A (es) 1998-07-31
FI972167A0 (fi) 1997-05-21
ATE193444T1 (de) 2000-06-15
PT793495E (pt) 2000-10-31
EP0793495A1 (en) 1997-09-10
EP0793495B1 (en) 2000-05-31
CY2166B1 (en) 2002-08-23
ZA959821B (en) 1996-07-31
WO1996015785A1 (en) 1996-05-30
DE69517332D1 (de) 2000-07-06
CZ154997A3 (en) 1997-10-15
GB9523667D0 (en) 1996-01-24
FI119355B (fi) 2008-10-31
DE69517332T2 (de) 2000-11-30
PL181179B1 (pl) 2001-06-29
NO972325L (no) 1997-05-22
IL116084A0 (en) 1996-01-31
US5955488A (en) 1999-09-21
JPH10508864A (ja) 1998-09-02
FR2727016B1 (fr) 1998-04-03
KR970706814A (ko) 1997-12-01
RU2159614C2 (ru) 2000-11-27
NZ296982A (en) 1998-06-26
BE1010250A3 (fr) 1998-04-07
NO306893B1 (no) 2000-01-10
HUT77886A (hu) 1998-09-28
CN1080118C (zh) 2002-03-06
TW398976B (en) 2000-07-21
HK1009591A1 (en) 1999-06-04
NO972325D0 (no) 1997-05-21
FR2727016A1 (fr) 1996-05-24
JP3001264B2 (ja) 2000-01-24
ITRM950762A0 (OSRAM) 1995-11-20
GR3033937T3 (en) 2000-11-30
US6063802A (en) 2000-05-16
FI972167L (fi) 1997-05-21
BR9509808A (pt) 1997-10-21
AU704160B2 (en) 1999-04-15
CN1171741A (zh) 1998-01-28
ITRM950762A1 (it) 1997-05-20
GB9423511D0 (en) 1995-01-11
GB2295318B (en) 1998-10-28
PL320295A1 (en) 1997-09-15
HU226891B1 (en) 2010-01-28
IT1282352B1 (it) 1998-03-20

Similar Documents

Publication Publication Date Title
ES2147309T3 (es) Composiciones de ondansetron liofilizadas.
ES2151083T3 (es) Composiciones orales que contienen ondansetron.
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ES2086546T3 (es) Productos de cemento de alta duracion conteniendo cenizas siliceas.
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
RU97110065A (ru) Высушенные замораживанием композиции ондансетрона
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
CY1107874T1 (el) Φαρμακευτικh σyνθεση επιβραδυνoμενης αποδεσμευσης φλουβαστατiνης
PA8562101A1 (es) Metodos para granulacion humeda de azitromicina
CO4940406A1 (es) Composiciones de paracetamol de accion rapida
SV2002000235A (es) Composiciones farmaceuticas que comprenden valdecoxib
PE20020329A1 (es) DERIVADOS DE 10-ARIL-11H-BENZO[b]FLUORENO Y ANALOGOS COMO COMPUESTOS ESTROGENICOS
ES2113533T3 (es) Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal.
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
AR011697A1 (es) Composiciones farmaceuticas, uso de lamivudina en la manufactura de tales composiciones farmaceuticas.
ES2136198T3 (es) Composiciones rectales que contienen odansetron en forma de su base libre.
ES2086536T3 (es) Uso de ketorolaco para el tratamiento de la enfermedad periodontal.
AR017215A1 (es) Composiciones que contienen generadores de oxido nitrico y uso de dichos generadores para la preparacion de un medicamento util para el tratamiento detrastornos de ojo seco
CA2205600A1 (en) Freeze-dried ondansetron compositions
AR030374A1 (es) Una composicion oral
AR036257A1 (es) Sulfamatos de 2-alcoxiestradiol de accion antitumoral
PA8508401A1 (es) Composiciones de valdecoxib
ES2191106T3 (es) Uso de ondansetron en la fabricacion de un medicamento para el tratamiento del temblor.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 793495

Country of ref document: ES